Filter posts

New Infographic: Balancing Need for Innovation with Competition

It is an underreported fact that the time it takes for a generic medicine to …

BIO Unveils Refreshed Advocate Toolkit

This past March, BIO launched DrugCostFacts.org, an interactive web tool designed to help policymakers, members of …

Save the Date: Human Genome Editing Webinar with NAS/NAM, FDA on February 22

DNA defines who we are. And like anything else, sometimes there are mistakes – mutations …

The Remedy to Beating America’s Opioid Crisis

Opioid abuse and addiction is one of the worst public health crises America has ever …

FDA’s No. 2 Official Sounds Off on Right to Try, Opioid Crisis

During his first State of the Union address two weeks ago, President Donald Trump expressed …

#BIOCEO18: Tackling the Opioid Crisis

Opioid addiction is plaguing communities across the country, leaving in its wake countless victims, devastated …

#BIOCEO18: “A Moment Decades in the Making”

It’s a first-of-its-kind gene therapy ever approved by the U.S. Food and Drug Administration, marking …

BIO Releases Report on Investment in Pain and Addiction Therapeutics

BIO’s Industry Analysis team has released its second report in a new series on the …

Is Your Emergency Worth It? Let’s Ask Your Insurer…

Imagine that it is 2AM and the pain is so severe that you cannot move. …

Give It a Shot – Protect Yourself from the Flu

Everyday it’s a new headline. The numbers keep rising. No, we’re not talking about the …